Wave Life Sciences has reported a modest 1% reduction in body weight after six months of treatment with its siRNA obesity drug candidate, WVE-007, leading to a dramatic 55% drop in its stock price. Despite the disappointing weight loss results, the company highlighted significant improvements in body composition, including a 14.3% reduction in visceral fat and a 3.3% decrease in waist circumference. Analysts from Mizuho Securities noted that these metrics are crucial for assessing the drug’s potential, suggesting that WVE-007 may still hold promise in an evolving obesity treatment landscape.

The focus on body composition rather than just weight loss reflects a growing trend in obesity therapeutics, as preserving lean mass while reducing fat becomes increasingly important. With the FDA’s benchmark for effective obesity drugs set at a 5% weight loss after one year, Wave’s future trials will be critical to validate its efficacy in a higher BMI population.

For longevity researchers, the implications of WVE-007’s approach may signal a shift in how obesity treatments are evaluated, emphasizing metabolic health over sheer weight loss.

Source: fiercebiotech.com